Compare AbCellera Biologics Inc (ABCL) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while Vanguard Total International Stock Index Fund ETF trades at $83.95. Which is the better fit depends on your goals.
| ABCL | VXUS | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Sector/Thematic |
52-Week High | $8.12 | $87.06 |
52-Week Low | $2.78 | $68.24 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
VXUS trades at $86.17, up 1.57% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides diversified international equity exposure across developed and emerging markets, holding over 8,700 stocks. Recent news highlights its role in portfolio diversification amid high U.S. valuations, with Vanguard surpassing iShares as the largest ETF provider in June 2026.
VXUS offers a strategic hedge against U.S. market concentration, trading at a discount to domestic peers. Key risks include currency fluctuations, geopolitical tensions, and emerging market volatility. Analyst sentiment is positive due to broad diversification and cost efficiency, though performance depends on global economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
